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Background: Carbapenems are the most effective and important therapeutic options to serious infections caused by 
Enterobacteriaceae and Pseudomonas aeruginosa isolates. However, Carbepenems resistant isolates of Enterobacteriaceae 
and Pseudomonas aeroginosa are increasing worldwide. This study, therefore, was carried out to determine the 
resistance pattern of clinical isolates of Pseudomonas aeruginosa and Escherichia coli to Carbapenems. 
Methods: Fifty (50) E. coli and forty seven (47) Pseudomonas aeruginosa isolates were studied. Antibiotic Susceptibility 
test was performed as recommended by the CLSI. The antibiotics used were Ertapenem, Imipenem, Colistin 
Sulphate, Levofloxacin, and Piperacillin/Tazobactam. 
Results: Out of 97 clinical isolates subjected to drug susceptibilities test, Pseudomonas aeruginosa showed resistance to 
Ertapenem (87.2%); followed by Levofloxacin (19.1%), Colistin sulphate (12.8%), Piperacillin/tazobactan (4.3%) and 
Imipenem (2.1%) while E.coli displayed resistance to Ertapenem (30%), Levofloxacin (20%) and Colistin sulphate 
(4%). Interestingly, E coli was susceptible to Imipenem (0%) and Piperacillin/tazobactan (0%). A significant effect of 
Ertapenem on Pseudomonas aeruginosa was recorded. Also a significant effect of Piperacillin/Tazobactam was 
recorded on E coli. No significant effect was recorded among the other antibiotics on P aeruginosa or E coli. 
Conclusion: There is a high level of Carbapenems resistance among the clinical isolates of Pseudomonas aeruginosa 
compared to Escherichia coli in this study. Considering the therapeutic value of Carbapenems as one of the last 
options for the treatment of Enterobacteriaceae and Pseudomonas aeruginosa infections, rational Carbapenems usage is 
essential to reduce selective pressure over Enterobacteriaceae and Pseudomonas aeruginosa clinical isolates. 
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Contexte : Carbapénèmes sont les plus efficaces et les options thérapeutiques importants d'infections graves causées par les 
entérobactéries et Pseudomonas aeruginosa isolats. Cependant, Carbepenems isolats résistants d'entérobactéries et 
Pseudomonas aeroginosa sont en augmentation dans le monde entier. En conclusion, cette étude a été réalisée pour déterminer 
le profil de résistance des isolats cliniques de Pseudomonas aeruginosa et Escherichia coli de carbapénèmes. 
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Méthodes: Cinquante (50) E. coli et quarante sept (47) des isolats de Pseudomonas aeruginosa ont été étudiés. Test de sensibilité 
aux antibiotiques a été effectuée comme recommandé par le QIMV. Les antibiotiques utilisés étaient l'ertapénème, imipenem, 
sulfate de colistine, Lévofloxacine, et de l'association pipéracilline-tazobactam. 
Résultats : Sur 97 isolats cliniques de médicaments soumis à des test de susceptibilité, Pseudomonas aeruginosa ont montré une 
résistance à l'ertapénème (87,2  %), suivie par la lévofloxacine (19,1  %), sulfate de colistine (12,8  %), l'association pipéracilline-
tazobactam (4,3  %) et l'imipénème (2,1  %) tandis que les E. coli affiche une résistance à l'ertapénème (30  %), la lévofloxacine 
(20  %) et sulfate de colistine (4  %). Fait intéressant, E coli était sensible à l'imipénème (0  %) et de la pipéracilline/tazobactam (0  
%). Un effet significatif de l'ertapénème sur Pseudomonas aeruginosa a été enregistrée. Aussi un effet significatif de 
l'association pipéracilline-tazobactam a été enregistré sur E coli. Aucun effet significatif n'a été enregistré parmi les autres 
antibiotiques sur P aeruginosa ou E coli. 
Conclusion : Il y a un haut niveau de résistance aux carbapénèmes parmi les isolats cliniques de Pseudomonas aeruginosa par 
rapport à Escherichia coli dans cette étude. Compte tenu de la valeur thérapeutique des carbapénèmes comme l'une des 
dernières options pour le traitement d'entérobactéries et Pseudomonas aeruginosa les infections, l'utilisation rationnelle des 
carbapénèmes est essentielle pour réduire la pression sélective sur les entérobactéries et Pseudomonas aeruginosa isolats 
cliniques. 
 




Antibiotic resistance of pathogenic organisms has 
become a worldwide problem with serious concern 
both in hospital and community settings posing 
threatening consequences on the treatment of 
infectious diseases. The increased use/misuse of 
antibiotics in human medicine, agriculture and 
veterinary is primarily contributing to the 
phenomenon (1, 2).  Pseudomonas aeruginosa is one of 
the most frequent (10-20%) pathogens associated to 
nosocomial infections, especially among 
immunocompromised patients (2) exhibiting 
notorious versatility and capacity to acquire 
resistance mechanisms to antimicrobial therapy(3).  
Within the hospital, P. aeruginosa finds numerous 
reservoirs in disinfectants, respiratory equipment, 
food, sinks, taps and mops. Spread occurs from 
patient to patient on the hands of hospital personnel, 
by direct patient contact with contaminated 
reservoirs, and by ingestion of contaminated foods 
and water (4).   
 
Mechanisms of resistance to Carbapenems in P. 
aeruginosa are impermeability, including closure of 
porin channels in the bacterial cell wall; and extrusion 
of antibiotics by efflux pumps, which can lead to 
resistance to multiple classes of antibiotics.  E. coli, on 
the other hand, produce extended-spectrum β-
lactamases (ESBLs) which may develop on the basis 
of a change in only one amino acid in the β-
lactamases normally produced (5). By contrast to 
plasmid-mediated production of ESBLs, AmpC β-
lactamases are chromosomally-mediated and occur in 
ICU pathogens such as P. aeruginosa, Enterobacter spp, 
and in recent years in E. coli (6).  
 
Carbapenems are a class of potent β-lactams 
considered as the last resort option for treating 
serious nosocomial infections caused by a broad 
spectrum of Gram-negative bacteria. They are known 
not to easily diffuse through the bacterial cell wall (7). 
They enter the Gram-negative bacteria through the 
outer membrane proteins (OMPs), after transversing 
the periplasmic space; Carbapenems ‘permanently’ 
acylate the penicillin-binding proteins (PBPs) which 
are enzymes that catalyze the formation of 
peptidoglycan in the cell wall of bacteria (8, 9, 10). 
Carbapenems act as mechanism-based inhibitors of 
the peptidase domain of PBPs which inhibits peptide 
cross-linking as well as other peptidase reactions. 
Carbapenems are prominent for their ability to bind 
to multiple different PBPs and eventually weakening 
the peptidoglycan ultimately leading to cell burst due 
to osmotic pressure (8, 11).  
Carbapenems resistance is modulated by acquired 
carbapenemases in association with intrinsic 
mechanisms such as down-regulation or loss of OPrD 
porin, efflux pumps hyperextension, chromosomal 
AmpC β-lactamase production, and target alterations. 
However, since carbapenemases have the ability to 
hydrolyse Carbapenems, Gram-negative bacteria 
carrying a carbapenemase-encoding gene frequently 
exhibit resistance to virtually all β-lactams. 
 
Majority of the non-fermenting Gram-negative 
bacteria (e.g., pseudomonas spp., Acinetobacter spp., and 
Stenotrophomonas spp.), as well as the 
Enterobacteriaceae (e.g., Klebsiella spp., Escherichia coli, 
and Enterobacter spp.) and Gram-positive bacteria 
(e.g., Staphylococcus spp., Streptococcus spp., 
enterococcus spp., Nocardia spp.), have shown 
resistance to most clinically available carbapenems 
and this is of grave public health concern (12). 
Given the importance of Carbapenem for the 
treatment of infections caused by P. aeruginosa and E. 
coli, this present study was carried out to examine the 
antimicrobial resistance pattern of Carbapenems on 
the clinical isolates of Pseudomonas aeruginosa and 




MATERIAL AND METHODS 
Collection of samples  
Ninety seven (97) isolates were obtained from the 
University College Hospital, comprising of fifty (50) 
E. coli and forty seven (47) Pseudomonas aeruginosa 
isolates. They were sculptured onto sterile slant 
bottles. They were transferred to the Microbiology 
Research Laboratory of Pure and Applied Biology, 
Ladoke Akintola University of Technology, 
Ogbomoso, Oyo State, South-Western part of Nigeria 
for further analysis.   
 
Processing of samples 
Inoculum preparation was done under asepsis by 
picking isolates from the slant bottles into universal 
bottles containing 5ml of normal saline to obtain a 
suspension equivalent to the turbidity of 0.5 
McFarland standards.  
 
Antibiotic susceptibility testing 
Susceptibility test was determined using the disc 
diffusion method on Mueller-Hinton agar plates and 
interpreted according to the recommendations of the 
Clinical and Laboratory Standards Institute (CLSI, 
2014) as described by (13). Five antibiotics were 
tested, including Ertapenem (10µg), Imipenem (10µg), 
Colistin Sulphate (25µg), Levofloxacin (5µg), and 
Piperacillin/Tazobactam (110µg).  
 
Statistical analysis 
Statistical analysis was carried out with the Statistical 
Package for Social Sciences (SPSS) version 20.0; 
ANOVA was done at p-value < 0.05 and at a 
confidence interval of 95%. 
 
RESULTS                                                                                        
Table 1 showed the antibiotics susceptibility profiles 
of the clinical isolates cum variation using disk-
diffusion methods. Pseudomonas aeruginosa had the 
highest resistance rates to Ertapenem (87.2%), 
followed by Levofloxacin (19.1%), Colistin sulphate 
(12.8%), Piperacillin/Tazobactam (4.3%) with the least 
resistance observed in Imipenem (2.1%).  
 
 
TABLE 1: THE ANTIBIOTICS SUSCEPTIBILITY PROFILES OF P. AERUGINOSA AND E. COLI 
Organisms (isolates)                                                              Antibiotics 
                           Ertapenem            Imipenem            Colisin sulphate       Levofloxacin         Piperacillin/tazobactam 
                               (10µg)                     (10µg)                        (25µg)                 (5µg)                          (110µg) 
                             S        I     R       S       I     R        S      I      R                S        I         R                S         I            R     
  
P. aeruginosa(% )4.3  8.5  87.2  4.3   93.6  2.1     6.4  80.9 12.8             80.9   0      19.1               89.4     6.4     4.3 
  
E. coli              56%  14%  30% 100%  0%   0%    90%  6%   4%          80%  0%   20%                96%     4%    0% 
Key: S= Susceptible, I= Intermediate and R= Resistant 
E. coli had the highest resistance rates to Ertapenem 
(30%) followed by Levofloxacin (20%). The least was 
recorded in Colistin sulphate (4%). No resistance was 
recorded in Imipenem and Piperacillin/Tazobactam, 
respectively. P. aeruginosa isolates had highest 
susceptibility to Piperacillin/Tazobactam (89.4%) 
followed by Levofloxacin (80.9%), Colistin sulphate 
(6.4%), with the least recorded in Imipenem and 
Ertapenem (4.3% each), respectively. E. coli had the 
highest susceptibility to Imipenem (100%) followed 
by Piperacillin/Tazobactam (96%), Colistin sulphate 
(90%), Levofloxacin (80%). The least was recorded in 
Ertapenem (56%).  These results suggest that 
Ertapenem is least effective against E. coli and P. 
aeruginosa since about 57.7% of these clinical specimen 
isolates are resistant to it, while 
Piperacillin/Tazobactam is most effective because 
about 92.8% of these organisms are susceptible to it.  
The result of ANOVA revealed a significant effect of 
Ertapenem on Pseudomonas aeruginosa. Also a 
significant effect of Piperacillin/Tazobactam was 
recorded on E coli. No significant effect was recorded 
among the other antibiotics on P aeruginosa and E coli 
(Table 2). 
TABLE 2: ANOVA FOR MEAN EFFECT OF ANTIBIOTICS ON ISOLATES 
Organisms Antibiotics 
 Ertapenem Imipenem Colisin sulphate Levoflox Piperacillin/tazobactam 
 
P. aeruginosa 1.27 + 0.07b 1.37 + 0.02a 1.95 + 0.03a 1.48 + 0.02a 0.88 + 0.00a 
E. coli 1.24 +0.40a 1.84 + 0.04a 1.32 + 0.01a 1.74 + 0.02a 2.32 + 0.05ab 
Key: Values are mean scores + standard error. a, b = Mean values followed by the same superscript in the columns are not 
significantly different by Duncan’s Multiple Range test (P < 0.05). 
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DISCUSSION                                                                    
Antibiotic resistance determinants have been 
circulating within the microbial genome for millennia, 
largely predating the manufacture and use of 
antibiotics by human beings (14).  Antibiotic 
resistance correlates well with the frequency of drug 
use and in a country like Nigeria where drugs are 
easily available over-the-counter, bacterial resistance 
to antibiotics grows rapidly, putting our health care 
system in a dilemma. Drug resistance facilitates 
growth and increases prevalent of persistent 
pathogens which become difficult to exterminate (15).  
P aeruginosa is the most common non-fermenting 
bacterium isolated from clinical samples posing a 
serious therapeutic threat for the treatment of both 
community-acquired and nosocomial infections. 
Identification and selection of appropriate antibiotic 
to initiate therapy is essential to optimizing clinical 
outcome. E. coli, on the other hand, produce 
extended-spectrum β-lactamases (ESBLs) which may 
develop on the basis of a change in only one amino 
acid in the β-lactamases normally produced (6).  By 
contrast to plasmid-mediated production of ESBLs, 
AmpC β-lactamases are chromosomally-mediated 
and occur in ICU pathogens such as P. aeruginosa, 
Enterobacter spp, and in recent years in E. coli (14).  
From this study, P aeruginosa had more resistance to 
the antibiotics used as compared with E coli. The 
study showed majority (87.2%) of P aeruginosa isolates 
were resistant to ertapenem, followed by levofloxacin 
(19.1%) and colistin sulphate (12.8%). Similar resistant 
pattern against the isolate was reported in different 
studies conducted by 16, 17 and 18. Imipenem and 
piperacillin/tazobactam were most effective drug 
observed in this study showing resistant rates of 2.1% 
and 4.3% respectively. This pattern is in accordance 
with the reports of  (19, 20, 21). 
On the other hand, E coli showed a major (30%) 
resistance to ertapenem followed by levofloxacin 
(20%) and Colistin sulphate (4%). This is in 
accordance with the findings of (22, 23, 24).  
Interestingly, the isolates were 100% susceptible to 
imipenem and piperacillin/Tazobactam, respectively. 
This is in accordance and in disagreement to the 
report of 26 who recorded 100% sensitivity for 
imipenem and nearly 40% sensitivity to 
piperacillin/Tazobactam.  
In Nigeria, the sensitivity of the isolates to imipenem 
and piperacillin/tazobactam is in accordance with the 
reports of (27, 28, 29). The high susceptibility pattern 
of these drugs could be associated to less drug abuse 
by the population due to their cost preventing 
patient’s self-medication.  However, the pattern 
disagrees with the findings of 30, 31 where a high 
resistant was recorded, thus demonstrating the 
evolution of imipenem-resistant strains of P. 
aeruginosa to imipenem. 
One of the reasons for resistance might be due to 
misuse and overuse of antibiotics, that is, not 
adhering to the prescription of antibiotics. Also, it can 
be transferred horizontally between bacteria. P. 
aeruginosa resistance to Carbapenems may be due to a 
result of complex interactions of several mechanisms 
including production of carbapenemase, 
overproduction of efflux system and loss of outer 
membrane porins (21). P aeruginosa resistance to 
imipenem and piperacillin/Tazobactam might be as a 
result of movement of various types of patients being 
referred to UCH, a tertiary hospital, both locally and 
internationally for management or continuation of 
therapy, thus the selective pressure of use, misuse 
and overuse of antibiotics cannot be farfetched. Also, 
there is the likelihood of transfer of resistance genes 
from other clinics around the world. 
Resistance in E coli might be as a result of transfer of 
plasmids between commensal organisms and 
potential pathogens through inappropriate or 
overprescribing of antibiotics and difficulty in 
establishing bacterial etiology at the time of 
prescription. Therefore, there is need for public 
awareness on the prudent use of antibiotics and strict 
adherence to minimize the misuse of effective drugs. 
Overall, the data obtained indicate that imipenem and 
piperacillin/Tazobactam are the most effective for the 
treatment of P. aeruginosa and E. coli infections. 
Though effective, proper monitoring of resistance to 
these antibiotics is necessary. 
 
Conclusion: This study revealed that most of the 
isolates were susceptible to imipenem and 
piperacillin/tazobactam. To avoid resistance, illicit 
use of antibiotics is advised. Continued monitoring of 
antimicrobial resistance patterns in hospitals and 
community settings is essential to guide effective 
empirical therapy. Furthermore, 
piperacillin/tazobactam may be considered as reserve 
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